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ABSTRACT
Parkinson’s Disease (PD) is a progressive neurodegenerative disease associated with loss of
dopamine-producing cells and characterized by tremors, stiffness and bradykinesia. The cause
of PD is unknown, however, both genetic and environmental factors play a role in the
pathophysiology. In this review, Ghrelin mediated neuroprotection, the use of exenatide and
bee venom as recent developments in the management of Parkinson’s disease was discussed.
The presence of Lewy bodies and α-synuclein in Lewy bodies has also been contraindicated
in the progression of this disease. Parkinsonism is considered to arise primarily from
abnormalities of basal ganglia function. Although Parkinson’s disease cannot be treated, its
progressive symptoms could be delayed by several methods which include the use of
anticholinergic agents, amantadine levodopa, monoamine oxidase inhibitors, catechol-O-
methyltransferase inhibitors and deep brain simulation. Despite numerous research on PD,
more recent and less evasive mechanisms have been researched upon to understand the root
cause of this disease. In this study, the possible cellular and molecular mechanisms
fundamental to the action and possible role of ghrelin, exenatide and bee venom in slowing
or preventing Parkinson's disease progression was considered.
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INTRODUCTION
Parkinson's Disease (PD) is a dynamic neurodegenerative malady found in 1917 by a
British specialist, Dr. James Parkinson's. It is caused by the loss of dopamine-producing
cells, characterized by tremors, stiffness and bradykinesia. Researchers theorize that PD
is considered as a non-motor disorder on the grounds that as the disease advances, side
effects, for example, depression, dementia and falls are perceived1. This disease affects
1% of the population over 60 years old, while it affects 2% of the population above 80
years of age with an increasing occurrence. In reported cases, there was large
variability’s of incidence rate because of difference in standard or criteria for diagnosis
and case ascertainment. Although it varies, the occurrence was usually 1.5 times much
more in males than females across different studies. Patients with Parkinson’s disease
have a lower life expectancy in comparison with the general population1. However, the
rate of people with Parkinson’s disease has declined in the past decades. When its
symptoms and drugs were included in the diagnosis, the annual rate of decline was 1%
but when only the diagnosis was considered, the rate of decline was 6%. Between 1990
and 2010, there was  an  assessment  in  the  rate  of  incidence  whereby  there  was  a
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Fig. 1: The Hoehn and Yahr scale5
reduction down to 55% in 2000. By 2010, the incidence of PD
was discovered to be 39% of what it was during the year 1990.
Therefore, the rate of PD has been continuously reducing.
Nevertheless, there has been a gradual increase in the rate of
incidence but only in men2. In the world, there were more
than 10 million people diagnosed with PD and there may be
more, but due to inconsistent unfinished studies and an
imprecise definition of Parkinson’s disease, the actual number
of people with this disease is yet to be known. There is a scale
which helps to universally examine the progression of
Parkinson’s disease, compare the groups and sort patients into
the stages known as the Hoehn and Yahr scale as shown in
Fig. 13,4. The aim of this review was to discuss Ghrelin
mediated neuroprotection, the use of exenatide and bee
venom as recent developments in the management of
Parkinson’s disease.
RISK FACTORS AND DIAGNOSIS
No known cause has been attributed to PD, factors such as
family history, environmental factors, lifestyle (illegal drugs,
medications, smoking), stroke, head trauma, brain
inflammation and sports have been associated with the
disease. The presence of specialized proteins (Lewy bodies) in
the brain cells6, genetics7 and presence of a-synuclein proteins
in the Lewy bodies7 are other factors associated with the
progression of PD. In diagnosing PD, physical examination has
to be employed. It concentrates on the common
characteristics of the disease which include tremors,
bradykinesia and rigidity in limbs, postural instability which
makes it difficult to walk or move. Also, the patient’s medical
history was usually looked into. Imaging tests like magnetic
resonance imaging (MRI), positron emission tomography (PET)
and dopamine transporter imaging (DAT) scans may be
performed to rule out other diseases that have similar
symptoms to PD5. Assessment of persistent kinetic tremor
manifestation such as classic rest tremor, predominantly
unilateral tremor, leg tremor, concomitant rigidity, which often
affects the limbs were done intensely to favour the diagnosis
of Parkinsonism8.
SYMPTOMS OF PARKINSON’S DISEASE
PD is characterized by motor and non-motor symptoms. For
motor symptoms, bradykinesia, rigidity and tremors are the
three major characteristics. Others include postural
deformities, postural instability and freezing5. Bradykinesia
could be diagnosed in other illnesses or disorders, its
nonetheless, the most distinct clinical feature of PD. It is
characterized by slowness of movement which results in
manifestations such as impaired swallowing leading to
drooling, monotonic and hypophonic dysarthria, loss of
impulsive movement, hypomimia (which is a loss of facial
expression). Rigidity is a distinct feature of this symptom,
leading to increased resistance which makes it hard to move
body parts causing pains  in  the process. It may happen
distally (ankles, wrist) or it may happen proximally (neck, hips,
shoulder) and often misdiagnosed as rotator cuff injury or
arthritis. Although not everyone gets tremors, this
uncontrolled shaking usually begins in the hand and arms and
then gradually moves to other parts of the body.  It could also
occur in the legs especially when the victim feels stressed or
when resting the hand. It was without problems recognized as
the most common symptom of PD. For the non-motor
features of PD, autonomic dysfunction such as orthostatic
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hypotension, sweating, erectile and sphincter dysfunction,
cognitive and neurobehavioral abnormalities such as apathy,
depression, hallucination and anxiety; sleep abnormalities
such as insomnia, sleepiness during daytime, having violent
dream content; sensory abnormalities such as paresthesia,
olfactory dysfunction, akathisia, oral and genital pain;
constipation, loss of smell and low blood pressure when you
stand up are usually present.
THE ROLE OF LEWY BODIES AND "-SYNUCLEIN IN
PARKINSON’S DISEASE
α-Synuclein is a neuronal and glial cell protein that aggregate
into insoluble fibrils to produce Lewy bodies which is a
pathological trait of PD. It is an eosinophilic inclusion
identified in neurons, with a surrounding pale halo and an
eosinophilic core as depicted in Fig. 29. They often are circular
or pleiomorphic. They can be detected in the brain displaying
the most loss of neuron in PD and also other parts of the body
like the spinal cord, peripheral autonomic ganglia, neocortex
etc. Although Lewy bodies have been known for many years
now, their formation or mechanism has been unknown. But
from various experiments and studies, there have been many
hypotheses on the formation of Lewy bodies which was
mainly from protein handling dysfunction. Molecular
composition of Lewy bodies has been interpreted using
conventional histological and immunohistochemical methods
by researchers as described in Fig. 310. These molecules
include ubiquitin, torsinA, α-synuclein and the α-synuclein-
binding protein synphilin-111.
They are formed by disrupting the equilibrium between
generation and breakdown of intracellular proteins. Over
expression of normal or mutant proteins (e.g., synuclein), or
other biochemical deformities that can cause protein harm
and build up is associated with PD. In these proteins,
phosphorylation, heat-shock proteins and ubiquitination
mechanisms are unsuccessful, making them undegradable
and aggregating with other normal and abnormal proteins.
These aggregates impair the ubiquitin-proteasome system
and hence further advance accumulation of protein. Under
these conditions, ubiquitinated proteins are actively
transported along microtubules to at least one centrosomes
situated in the perinuclear area. The centrosomal structure
extends to be an aggresome then enclosed by a system of
filaments like neurofilaments, synuclein etc. Aggresome
expands proteolysis such that abnormal proteins break down
and compartmentalize to ensure the protection of intracellular
Fig. 2: Lewy body in a neuron9
Fig. 3: (a) Conventional haematoxylin (blue) and eosin (pink)
histological staining reveals a spherical Lewy body
(arrow) in SNc dopamine neurons with a distinct central
core and a peripheral halo, (b) Electron microscopic
view of Lewy bodies reveals presence of outer halo
composed of radiating filaments and granular material
in the core. Immunohistochemical protocol shows (c)
two Lewy bodies (arrow) with ubiquitin concentrated
in the core (C) and (d) two Lewy bodies (arrow) with "
synuclein concentrated in the halo10
organelles and molecules. If this process occurs, protein
aggregates will be cleared and if not (due to lack of
ubiquitin-proteasome system function or over-production of
abnormal proteins), continuous aggresome growth and Lewy
body formation are hypothesized (Fig. 4)11. The fate of Lewy
bodies may fluctuate with some seen in surviving neurons and
others discovered free in the extracellular space. These
consistencies with their conservation after the destruction of
the host neuron were observed12.
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Fig. 4: Formation of Lewy bodies11
Fig. 5: Anatomy of basal ganglia14
In different situations, Lewy bodies may  have  been destroyed
by the autophagic system as has been reported for
aggresomes   or  engulfed  with  the  host  neuron  by
activated microglia, which were spotted at pathological points
in PD.
THE BASAL GANGLIA
The basal ganglia is situated at the base of the forebrain
(cerebrum) and has been considered as a therapeutic target
for dysfunctions caused by sicknesses or injury. Different
automatic developments, including chorea, ballism, athetosis,
dystonia and trouble in the execution of deliberate or
common movement in Parkinsonism have been portrayed
clinically and their relationship with pathological changes in
the basal ganglia were set up at the beginning of the 20th
century13. 
The basal ganglia frame a complex system of parallel circles
which coordinate cerebral regions (cooperative, oculomotor,
limbic and motor). The thalamus, caudate nucleus, putamen,
subthalamic nucleus, substantia nigra and globus pallidus
located in the base of the forebrain make up the anatomy of
the basal ganglia (Fig. 5). The  motor  circuit  can  be
specifically identified with the pathophysiology of movement
disorders. Cortical motor areas project in a somatotopic
fashion to the postero-lateral putamen where they set up
excitatory, glutamatergic synaptic connections with medium
spiny neurons containing GABA. These neurons offer ascent to
two pathways that interface the striatum to the output cores
of the basal ganglia, to be specific the Globus pallidus pars
internal (GPi) and the substantia nigra pars reticulata (SNr).
Neurons in the 'direct pathway' project directly from the
putamen to GPi/SNr. They bear dopamine D1 receptors,
coexpress the peptides substance P and dynorphin and give
a direct inhibitory impact on GPi/SNr neurons. Striatal neurons
in the 'indirect pathway' associate the putamen with the
GPi/SNr by means of synaptic associations in the globus
pallidus pars externa (GPe) and subthalamic core (STN). They
contain D2 receptors and the peptide enkephalin (ENK).
Projections from putamen to GPe and from GPe to STN are
GABAergic   and  inhibitory.  Neurons  beginning  in  the  STN
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Fig. 6: (a) Direct and (b) Indirect pathway of the basal ganglia17, GPe: Globus Pallidus externus, GPi: Globus Pallidus internus, SNc:
Substantia Nigra pars compacta, SNr: Substantia Nigra pars reticulata and STN: Subthalamic nucleus
utilize glutamate as a neurotransmitter and enact neurons in
the GPi/SNr. Incitement of neurons in the indirect pathway
prompts restraint of the GPe, disinhibition of the STN and
excitation of the GPi/SNr. In this way, the contradicting
impacts of inhibitory inputs from the direct pathway and
excitatory inputs from the indirect pathway affects the output
movement of the basal ganglia. This gives an inhibitory impact
on brainstem and thalamocortical neurons engaged with
motor exercises. The occurrence of movement was related to
delays in the neuronal movement of GPi/SNr neurons. The
initiation of neurons from the direct and indirect pathways
encourages and smothers motor action, separately. In this
way, the direct and indirect pathways affect the capacity of
the basal ganglia as presented in Fig. 615,16. 
In the parkinsonian state, the fundamental pathophysiologic
feature increases the neuronal movement in GPi/SNr output
nuclei of the basal ganglia, which leads to too much inhibition
of thalamocortical and brainstem motor frameworks. The
model predicts that lessened activation of dopamine
receptors, caused by lack of dopamine, results in diminished
inhibition of neurons of the indirect pathway and diminished
excitation of neurons of the direct pathway. Lessened
inhibition from the indirect pathway prompts over-inhibition
of the GPe, disinhibition of the STN and increased excitation of
GPi/SNr neurons, while diminished activation from the direct
pathway causes a decrease in its inhibitory impact on the
GPi/SNr. Excessive activation of basal ganglia output neurons
joined by unnecessary restraint of motor frameworks,
prompting parkinsonian motor characteristics becomes the
net outcome (Fig. 7)18,19.
MANAGEMENT OF PARKINSON’S DISEASE
Symptomatic treatment: The conventional method in
handling the treatment of patients with PD involves
dispensation of drugs to ease its symptoms.
Fig. 7: Mechanism of basal ganglia15,20, The thickness of the
arrows indicates the strength of the connections. Loss
of substantia nigra neurons leads to increased thalamic
inhibition. D1 and D2 indicate postsynaptic dopamine
receptor type, GPe: Globus pallidus externus, GPi:
Globus pallidus internus, SNc: Substantia nigra pars
compacta, SNr: Substantia nigra pars reticulata, STN:
Subthalamic nucleus and Thal, thalamus
Anticholinergic agents: Anticholinergic drugs such as
trihexyphenidyl and benztropine, faintly affect the clinical
signs of Parkinson’s disease by correcting balance between
dopamine and  acetylcholine  winding  up  towards
cholinergic predominance  in  the  striatum  of  patients with
PD21. They are used to control tremor, however, in cases of
rigidity or bradykinesia, they are sparingly used. They elicit
adverse effects on both the  central  and  peripheral  nervous 
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Fig. 8: Mechanism of levodopa24
system. These effects include impairment of memory and
hallucinations, impaired ocular accommodation, dryness of
the mouth, constipation, urinary retention and
vasodilatation21.
Amantadine: Amantadine looks like the anticholinergic drugs
in numerous ways, however, it frequently leads to some
change in rigidity. Despite its unestablished therapeutic
mechanism, its adequacy was found by chance. Its side effects
are like that of anticholinergic drugs due to structure similarity,
yet also, livedo reticularis of the legs and ankle oedema are
other side effects that occur21.
Levodopa: Levodopa is a dopamine precursor which is the
foundation of symptomatic treatment22. It is decarboxylated
to dopamine and consequently acts on the dopamine
receptors (Fig. 8)23. Unfortunately, the abnormal state of
levodopa viability was defaced by obvious undesirable
activities that turn out to be prominent with  the  disease. It
has been contended that levodopa deleteriously affects
neuronal survival in the substantia nigra, yet proof of this
impact was restricted and uncertain. Levodopa is typically
regulated with a peripheral  decarboxylase inhibitor;
carbidopa or benserazide, to lessen symptoms, for example,
nausea due to the decarboxylation of levodopa to dopamine
outside the blood-brain barrier. A few combinations of
levodopa and a peripheral  decarboxylase inhibitor were
accessible21,24. Despite the insufficient evidence to support the
toxicity of levodopa in humans, patients treated with
levodopa showed a decrease in dopamine transporters after
neuroimaging. This may suggest the possibility of some toxic
effect as well as pharmacologic down-regulation of the
transporters25.
Monoamine oxidase inhibitors: They hinder the oxidative
breakdown of dopamine by inhibiting monoamine oxidase.
Selegiline hydrochloride (deprenyl; Eldepryl, Somerset) inhibits
this enzyme26. It is utilized in this way to increase the impact of
dopamine by impeding its breakdown and treat patients in
whom administered levodopa is either losing its effects or
prompting fluctuations27. Increased monoamine oxidase B
activity, reduced glutathione levels and diminished activity of
antioxidant enzymes are synonymous with the substantia
nigra of patients with Parkinson's disease contains. This leads
to the oxidative deamination of dopamine28. Type B
monoamine oxidase inhibitors protect against oxidative
damage and thereby slow the progression of the disease29,30.
The limitation was the non-selective effect of these
inhibitors25.
Catechol-O-methyltransferase inhibitors: The inhibition of
dopa decarboxylase (by the carbidopa component of Sinemet)
prompts a compensatory action of different pathways for the
metabolism of levodopa, particularly catechol-O-
methyltransferase (COMT) which prompts expanded
circulating levels of 3-O-methyldopa31. The 3-O-methyldopa
competes with levodopa for an active carrier mechanism
associated with its transport over the intestinal mucosa and
the blood-brain barrier (Fig. 8). Particular COMT inhibitors may
in this manner enhance the advantages of levodopa  therapy
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Fig. 9: Locations where electrodes can be implanted for deep brain stimulation32
by reducing the conversion of levodopa to 3-O-methyldopa
and expanding the accessibility of levodopa in the mind itself.
Clinical investigations are as of now in advancement to assess
their therapeutic functions27. 
Deep brain stimulation: Thalamotomy and thalamic
stimulation involve the use of electrodes connected to an
impulse generator implanted into the chest. The generator
sends impulses through wires to the electrodes which are
implanted into the substansia nigra (Fig. 9). During the
surgery, the patient would be awake and asked to perform
certain tasks like wiggling their toes or clapping their hands to
know exactly which point the electrode was to be placed17,32.
In cases of advanced PD, when medications were no longer
controlling motor symptoms adequately, deep brain
stimulation (DBS) was used as a powerful therapeutic
alternative33. The major side effect associated with DBS is as a
result of unintended stimulation of structures adjacent to the
intended target. However, the complication was reduced
when used bilaterally34.
RECENT ADVANCEMENTS IN PD TREATMENT
Ghrelin mediated neuroprotection: Calorie Restriction (CR)
without malnutrition has been connected to lessening the
occurrence of a few neurodegenerative diseases. While the
mechanisms underlying this impact are not clear, there might
be mediation by the gastrointestinal hormone, ghrelin which
is secreted from the stomach during CR to alarm the brain on
changes in metabolic status and to advance re-feeding.
Ghrelin is a 28 amino-acid hormone that is elevated during CR,
a unique reaction as other gastrointestinal hormones are
increased by feeding to induce satiety. Initiation of the ghrelin
gene prompts the transcription and translation of the
preproghrelin peptide that was consequently cleaved  into
two known products-unacylated ghrelin (UAG) and obestatin.
UAG  can  experience  post-translational acylation by ghrelin
O-acyltransferase (GOAT) to form acyl-ghrelin (AG). Acyl-
ghrelin upregulates the calcium/calmodulin-dependent
protein kinase-B (CAMK), which enacts AMP-activated protein
kinase (AMPK), acyl-ghrelin regulates AMPK capacity to
advance  neuronal  survival33.  Also,  CR  increases  circulating 
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Fig. 10: Mechanism of ghrelin35, Autophagy-related (ATG), Leucine-rich repeat kinase 2 (LRRK2), Peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC-1")
acyl-ghrelin which crosses the blood-brain barrier (BBB) and
binds growth hormone secretagogue receptor (GHSR) leading
to activation of Ca2+/calmodulin-dependent protein kinase
(CaMK) and AMPK-mediated autophagy by up-regulating
sirtuins (SIRTS) or the formation of the Unc-51 like autophagy
activating kinase (ULK) complex. In addition, AMPK may inhibit
mechanistic target of rapamycin (mTOR) to induce autophagy,
whilst promoting uncoupling protein 2 (UCP2) dependent
changes in mitochondrial biogenesis results in adaptations to
mitochondria and autophagic flux, leading to
neuroprotection35, hence corroborating the putative
mechanism portrayed in Fig. 10.
Bee   venom:   It   contains   numerous   active   substances
(e.g., peptides, catalysts and biogenic amines) with various
pharmacological activities. In spite of the fact that BV can
cause neurotoxic and nociceptive impacts, it  likewise  has
anti-nociceptive, radioprotective and anti-mutagenic effects.
In this way, it has been utilized as conventional therapy for a
few sicknesses, for example, rheumatoid joint inflammation,
asthma, growth and skin illnesses. It tends to be applied as a
cream, ointment, liniment, injection, needle therapy, or
specifically through a living bee. Mellitin, a 26 aminoacid
peptide, is the essential part of BV (40 to 60%). At low doses,
it can increase capillary permeability, exert anti-inflammatory
effects and lower blood pressure. It has been demonstrated to
hinder apoptosis in SH-SY5Y cells and moderate the
inflammatory reaction of microglial cells. Another part of BV is
apamin (2% of BV content), an 18 aminoacid peptide, that was
generally perceived as an irreversible blocker of Ca2+ initiated
K+ channels. These channels were in charge of neuronal
hyperpolarization and for the most part, found in AMPA and
NMDA glutamatergic neurotransmitters. In this way,
obstructing these channels can decrease hyperpolarizing
impacts, improve synaptic plasticity and memory capacities.
In addition, BV contains phospholipase A2 (PLA2), a
compound that catalyzes the hydrolysis of layer
phospholipids, plays an essential job in signal transduction
and regulates inflammatory responses36. Attenuation of
neuroinflammation and microglial activation, inhibition of
apoptosis in dopaminergic neurons, protection against
glutamate-induced neurotoxicity and restoration of normal
brain neurochemistry were the major proposed mechanisms
of bee venom therapy on PD as illustrated in Fig. 1136.
Exenatide: Exenatide is a glucagon-likepeptide 1 (GLP-1)
mimetic, based on the peptide exendin-4. Unlike GLP-1, when
administered peripherally it can cross the blood-brain barrier
in humans influencing cellular processes37. This was as a result
of the inability of dipeptidylpeptidase-4 (DPP-IV) which
degrades GLP-1 to degrade it. This compound has
demonstrated neuroprotective- and neurotrophic- effects in
different models of neurodegenerative diseases38,39. Various
studies has reported GLP-1 receptor stimulation preserved
mitochondrial function in dopaminergic neurons by
increasing expression of complex I and anti-apoptotic proteins
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Fig. 11: Proposed mechanisms of bee venom therapy36
Fig. 12: Influence of neuronglucagon-like peptide 1 receptor (GLP-1R) activation on pathways in Parkinson's Disease (PD)
pathogenesis39, Bcl-2: B cell lymphoma 2, BAD (Bcl-2) antagonist of death, Bcl-XL: B cell lymphoma 2 extra-large, cAMP:
cyclic AMP, CREB: cAMP response element-binding protein, FoxO1/O3: Forkhead box O1/O3, GSK-3B: Glycogen synthase
3 beta, LTP: Long-term potentiation, mTOR: mammalian target of rapamycin, NF-6B: Nuclear factor kappa-light-chain-
enhancer of activated B cells, TNF: Tumour necrosis factor
Bcl-2 while reducing caspase-3 activation, leading to
attenuation of cell death (Fig. 12)40,41.
Exenatide provides complete protection against dopaminergic
cell loss by suppressing activation of microglia and
attenuating the expression of pro-inflammatory molecules
leading to improved performed on motor assessments42.
Reported mechanisms of exenatide such as cellular
proliferation,      differentiation,        inflammatory     pathways,
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Fig. 13: Exenatide activation of glucagon-like peptide 1 receptor (GLP-1R) in neurons42
mitochondrial function and dopaminergic survival were
associated with restoration and reversal of motor deficits in
various animal models of PD (Fig. 13). These proposed
mechanisms may have therapeutic benefits in the treatment
and management of PD patients42.
CONCLUSION
It was concluded that the cause of PD is usually due to loss of
certain neuron in the brain and scientists are yet to find its
treatment, but there have been several new methods
developed that can delay the progression of the disease and
help relieve patients from most of its symptoms. Nonetheless,
more recent mechanisms should be further researched upon
to understand the root cause of this disease thereby,
improving potential drug design and delivery.
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